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Atomic force microscopyCancer remains a major cause of morbidity and mortality worldwide. Although progress has been made regard-
ing chemotherapeutic agents, new therapies that combine increased selectivity and efﬁcacy with low resistance
are still needed. In the search for new anticancer agents, therapies based on biologically active peptides, in par-
ticular, antimicrobial peptides (AMPs), have attracted attention for their decreased resistance development
and low cytotoxicity. Many AMPs have proved to be tumoricidal agents against human cancer cells, but their
mode of action is still controversial. The existence of common properties shared by the membranes of bacteria
and tumor cells points to similar lipid-targeting mechanisms in both cases. On the other hand, anticancer pep-
tides (ACPs) also induce apoptosis and inhibit angiogenesis. Human neutrophil peptide-1 (HNP-1) is an endog-
enous AMP that has been implicated in different cellular phenomena such as tumor proliferation. The presence
of HNP-1 in the serum/plasma of oncologic patients turns this peptide into a potential tumor biomarker. The
present work reveals the different effects of HNP-1 on the biophysical and nanomechanical properties of solid
and hematological tumor cells. Studies on cellular morphology, cellular stiffness, and membrane ultrastructure
and charge using atomic force microscopy (AFM) and zeta potential measurements show a preferential binding
of HNP-1 to solid tumor cells from human prostate adenocarcinoma when compared to human leukemia cells.
AFM also reveals induction of apoptosis with cellular membrane defects at very low peptide concentrations.
Understanding ACPs mode(s) of action will certainly open innovative pathways for drug development in cancer
treatment.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
As cancer remains a signiﬁcant cause of morbidity and mortality
worldwide [1], it is important to rationally analyze the efﬁcacy of con-
ventional therapies and assess its impact on patient's survival and qual-
ity of life [1,2]. One of the inspirational sources for anticancer drug leads
is the group of so-called antimicrobial peptides (AMPs) [3,4]. In addition
to antimicrobial activity, these naturalmolecules act as conserved effec-
tors in innate immunity [4,5]. Interestingly, many AMPs have proven
anticancer activity against human cancer cells [6–9]. The modes of
action of these molecules have been extensively studied [10–14], and
they have attracted attention since they combine decreased resistance
development with low cytotoxicity. AMPs act mainly on the cell mem-
branes via a non-receptor-mediated pathway; therefore, it is difﬁculticancerpeptides;HNP-1,human
s, root-mean-square roughness;
; GAGs, glycosaminoglycans
351 217999477.
aofreire@fm.ul.pt (J.M. Freire),
(J.T. Barata),for cancer cells to develop resistance [15], which makes AMPs with an-
ticancer activity desirable molecules to be developed as new chemo-
therapeutic drugs. In addition to membranolytic action, it has been
proposed that anticancer peptides (ACPs) trigger intracellular mecha-
nisms of toxicity in tumors [7,16]. Like AMPs, many ACPs have the abil-
ity to translocate cell membranes [17] and reach intracellular targets.
The activity and selective cancer cell targeting ability of ACPs rely great-
ly on the increased negative membrane net charge as well as on differ-
ences ofmembrane ﬂuidity presented by tumor cellswhen compared to
normal tissues [15,18].
Defensins are a group of cationic AMPs that have been isolated from
different species [19], being the α- and β-defensins from human origin
the most intensively studied [20]. α-Defensins are the human neutro-
phil peptides, or HNPs, which are major components of the azurophilic
granules of neutrophils [21,22] in which concentrations of ~10 mg/ml
can be achieved [23]. These 30 amino acid residue peptides are produced
and released in response to microbial invasions, rapidly inactivating a
large spectrum of potential pathogens, either Gram-positive or Gram-
negative bacteria, and yeasts [24]. Their effect in cell division, attraction,
and differentiation of immune cells and wound healing has been also
described [25]. Importantly, the human neutrophil peptide-1, HNP-1,
as for other AMPs, showed simultaneous antimicrobial and anticancer
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prognostic biomarker in cancer [28–34] since it has been detected in ep-
ithelial tumors and is associated with tumor necrosis when expressed
intratumorally [35,36]. Up-regulated in cancers such as bladder, gastric,
and colorectal [29,33,34], the role of HNP-1 on the tumor microenviron-
ment and directly on the cancer cell is still unclear. Although it is known
that the HNP-1 damages cell membranes and enters cells [37], the exact
mechanism of cell death has remained elusive for more than 20 years.
In this work, we show the effects of HNP-1 on human prostate ade-
nocarcinoma (PC-3) and human acute lymphoblastic leukemia (MOLT-
4) cells using spectroscopic techniques and atomic force microscopy
(AFM). AFM techniques resolve the cellular ultrastructure at the nano-
meter scale [38]. In oncology, AFM has been used to reveal details of
the cell membrane structure and morphology [39–41], interaction
with different molecules [42], and elasticity [40,41,43]. In the present
study, results on cellular morphology, stiffness, and biomembrane
biophysical properties such as surface density charge and roughness
allowed the identiﬁcation of the cellular structures that are damaged
by HNP-1. These damages interfere with cells' ability to migrate and
invade different organs after interacting with HNP-1.
2. Materials and methods
2.1. Biological material and reagents
Human neutrophil peptide-1 (HNP-1; Ala-Cys-Tyr-Cys-Arg-Ile-Pro-
Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Tyr-Gly-Thr-Cys-Ile-Tyr-Gln-Gly-Arg-
Leu-Trp-Ala-Phe-Cys-Cys: Cys2-Cys30, Cys4-Cys19, Cys9-Cys29) was pur-
chased from Bachem. Adherent cancer cell line PC-3 (human prostate
adenocarcinoma) and suspension cell line MOLT-4 (human acute lym-
phoblastic leukemia) were purchased from American Type Culture
Collection (ATCC, CRL-1435, and CRL-1582, respectively). RPMI-1640
media, heat-inactivated fetal bovine serum (FBS), penicillin and strepto-
mycin solution, 200 mM glutamine solution, and trypsin EDTA were
obtained from Life Technologies. Glutaraldehyde was from Sigma.
2.2. Cell culture
Adherent cancer cell line PC-3was cultured as amonolayer in RPMI-
1640 media supplemented with 10% FBS, 2 mM glutamine, 100 U/ml
penicillin, and 100 U/ml streptomycin and maintained at 37 °C and 5%
CO2 in a humidiﬁed environment. MOLT-4 cell line was cultured in
suspension in RPMI-1640 media supplemented with 10% FBS and
2 mM glutamine and also maintained at 37 °C and 5% CO2 in a humidi-
ﬁed environment.
2.3. Cell live/dead assay using ﬂow cytometry techniques
The cytotoxicity of HNP-1 against PC-3 andMOLT-4 cells was evalu-
ated using a LIVE/DEAD® Viability/Cytotoxicity Assay Kit (L-3224) ob-
tained from Life Technologies. This kit is based on the use of two
ﬂuorescent probes, calcein AM, and Ethidium homodimer-1 (EthD-1)
that are sensitive to intracellular enzymatic activity and plasma mem-
brane integrity, respectively. The use of these probes allows discrimi-
nating between live and dead cells after interaction with HNP-1. Live
cells display green and dead cells red ﬂuorescence, respectively. Calcein
AM is a cell permeable probe, which is converted by intracellular ester-
ase activity, ubiquitous in live mammalian cells, to green ﬂuorescent
(530 nm) calcein. Dead cells are stained by EthD-1 dye, which binds
to cellular DNA of cells with their membrane compromised/perme-
abilized. Double staining also occurs in dead cells, indicating that some
esterase activity remained prior to cell damage and further cell death
[44]. Conﬂuent PC-3 cells were washed with phosphate buffer saline
(PBS) after trypsinization, while MOLT-4 cells were directly washed
with PBS. Cells were counted with a cell counter (Scepter 2.0 from
Milipore), diluted to 7 × 105 cell/ml and incubated for 4 h at 37 °Cwith increasing concentrations of peptide up to 10 μM, previously dis-
solved in PBS buffer. This incubation was performed in culture medium
supplemented without serum. Cells were then washed and suspended
in PBS buffer. Cell labeling with calcein AM and EthD-1 was performed
according to the manufacturer's instructions. Brieﬂy, 2 μL/ml of calcein
AM and 4 μL/ml of EthD-1 stock solution were added to each sample
and incubated 20min at room temperature protected from light before
measurement. Sampleswere loaded into a 96-wellmicroplate, and each
well was acquired using a BD LSR Fortessa cell analyzer equippedwith a
high throughput screening (HTS)module and a 488 nm laser. Eachmea-
surement consisted in collecting and recording the events of 180 μL of
each sample. Calcein green ﬂuorescence and EthD-1 red ﬂuorescence
emission were recorded using 530/30 and 610/20 band-pass ﬁlters,
respectively. Live and dead control populations were also measured
for proper live and dead populations discrimination and gating. Dead
cells were obtained by inducing cell death with 70% isopropanol solu-
tion. Forward and side scatter data were also collected to evaluate cell
damage and morphology changes induced by HNP-1. The percentage
of HNP-1-induced cell death/damage was calculated according to con-
trol cell population gating and manufacturer's instructions. The peptide
concentration required to kill half of the cancer cells (IC50) was calculat-
ed by ﬁtting a sigmoidal dose–response function [45] to cell death
percentage data as a function of HNP-1 concentration using GraphPad
Prism v6.0 analysis software.
Each sample was collected in triplicate and in two different days
using independent cellular suspensions.
2.4. Zeta potential measurements of live PC-3 and MOLT-4 cells in the
presence of HNP-1
The surface charge density of the cancer cells and the electrostatic
attraction of HNP-1 toward them were evaluated using zeta-potential
technique. Charged particles that are suspended in solution attract
ions with opposite charge to their surface. These ions cover the particle
surface and bound to it very strongly, forming the Stern layer. In addi-
tion to this layer, a second one is formed where the ions diffuse more
freely. When the particle diffuses through the solution, the strongly
bound ions move with it, contrary to the ions located in the diffuse
boundary. The zeta-potential is the potential that exists at this boundary
and can be determined by the electrophoretic mobility of the particles
in solution [46]. For these experiments, conﬂuent PC-3 cells were
washed with PBS buffer after trypsinization. Cells were diluted to 1
× 105 cells/ml in PBS buffer. MOLT-4 cells were washed with PBS
buffer, counted and diluted to 2.5 × 105 cells/ml in PBS buffer. Cellular
suspensions with and without HNP-1 (0–10 μM) were dispensed into
disposable zeta cells with gold electrodes and allowed to equilibrate
for 30 min at 37 °C. A set of 15 measurements (~40 runs each) were
performedwith a constant voltage of 40V. Control valueswere obtained
by measuring the surface charge of each cellular suspension in the
absence of HNP-1 (0 μM). The complete experiment was carried out at
least two times using independent cellular suspensions.
2.5. Atomic force microscopy imaging
AFM images were acquired using a JPK Nano Wizard II (Berlin,
Germany) mounted on a Zeiss Axiovert 200 inverted microscope
(Göttingen, Germany). The AFM head is equipped with a 15-μm
z-range linearized piezoelectric scanner and an infrared laser. PC-3
cells were culture in monolayer on IbiTreat 35 mm μ-dishes from Ibidi
at 5 × 104 cell/ml for 2 days. For control images, the culture medium
was replacedwith newmedium supplementedwithout serum followed
by an incubation of 4 h. Since we were interested in observing in detail
the membrane structure, we proceeded to cell ﬁxation with glutaralde-
hyde before imaging. After culture media removal, cells were washed
with PBS buffer and then ﬁxed for 10 min at room temperature in 2%
glutaraldehyde solution, washed with PBS and sterile mili-Q water,
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endure in HNP-1 presence, cells grown for 2 days on the IbiTreat
μ-dishes were added of new culture medium supplemented without
serum and with 5 μM HNP-1 ﬁnal concentration. Cells and peptide
were incubated for 4 h and then washed and ﬁxed using the same pro-
cedure for control samples.Measurementswere carried out in air and in
intermittent contact mode using uncoated silicon ACL cantilevers from
Applied NanoStructure (Santa Clara, CA, USA). ACL cantilevers had
typical resonance frequencies between 145 and 230 kHz and an average
spring constant of 45N/m. Cells wereﬁrst visualized through the optical
microscope before being selected for imaging. Due to irregular cellular
size and shape, total scan areas with 70 × 70 to 75 × 75 μm were
imaged with a resolution of 512 × 512 pixels and scan speeds lower
than 1 Hz. Height and error images were recorded and images were
line ﬁtted as required. The height proﬁle of 10 treated and 12 untreated
cells, was acquired through a cross section of each cell using the JPK
SPM Data Processing version 4.2.61. The surface roughness of control
and HNP-1-treated PC-3 cells was deﬁned as the root-mean-square
roughness (Rms) calculated from AFM height images and using
Gwyddion software version 2.33 [47]. Rms values were obtained
from the whole cell but also from different areas, namely, nucleus
and cytoplasm. Squared areas of 2.5 × 2.5 μm were selected andFig. 1. Effects of human neutrophil peptide-1 (HNP-1) on tumor cell viability and surface char
(PC-3, A) and human acute lymphoblastic leukemia cells (MOLT-4, B) were incubated with H
determined by ﬂow cytometry using a LIVE/DEAD assay kit (upper correlogram) using calcein
respectively. HNP-1-induced changes in cell morphology (lower correlogram) were used to fo
live and dead population gate discrimination (green and red, respectively). The percentage of H
over total cell population. Alterations in cellmembrane charge density in the presence of HNP-1
days using independently grown cell cultures. *0.01 b p-value b 0.05; **0.001 b p-value b 0.01;assigned as nuclear, cytoplasmic, or cell boundaries and ﬁnally ana-
lyzed. The Rms median of each group of squares corresponds to the
ﬁnal Rms value of the cellular component (nuclei and cytoplasm).
Rms of the whole cell was calculated as the median of all squares ana-
lyzed (nuclei, cytoplasm, and cell boundaries). Cells were observed
and imaged throughout three different days in different passages using
independent grown cultures.
2.6. Young's modulus (E) of prostate tumor cells determination
All studies were conducted using a JPK Nano Wizard II (Berlin,
Germany) mounted on a Zeiss Axiovert 200 inverted microscope
(Göttingen, Germany). The combination AFM-optical microscope
allows the lateral positioning of the AFM tip over the cell body with mi-
crometer precision. Elasticity measurements were performed on live
cells cultured as described previously for AFM imaging (control and
HNP-1-treated samples). The culture medium was removed and the
cells washed and kept in PBS buffer at room temperature. Data collec-
tionwas carried out until 1 h after initializing themeasurements for en-
suring the healthiness of the cells. After that, a new μ-dishwas observed.
Triangular-shaped silicon nitride cantilevers (OMCL-TR400PSA-1,
Olympus) were used for indenting the center of PC-3 cells, typicallyge density of solid and hematological tumor cells. Human prostate adenocarcinoma cells
NP-1 up to a maximum concentration of 10 μM for 4 h. The killing activity of HNP-1 was
(green) and ethidium homodimer-1 (red) ﬂuorescent dyes to detect live and dead cells,
llow cellular alterations (blue). Live and dead control populations were used for proper
NP-1-induced cell death/damagewas calculated according to population gating frequency
were followed by zeta potentialmeasurements. All experimentswere repeated in different
***0.0001 b p-value b 0.001; ****p-value b 0.0001.
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0.02 N/m) were calibrated by the thermal noise ﬂuctuations method
[48] before and after use and no change between the values was detect-
ed. Force curves (three per cell) were obtained at a maximum applied
force of 400 pN, sufﬁcient to allow a good signal-to-noise ratio without
damaging the cells. The Hertz model was ﬁtted to the approach curves
for extracting the Young's modulus (E). The measurement point was
selected in order to reduce the lateral heterogeneity of the mechanical
response that is expected from live cells. The procedure was repeated
in at least three different days using independently grown cultures in
different passages in a total of 59 untreated and 30 treated cells.2.7. Statistical analysis
Quantitative data were processed with Excel 2007 (Microsoft, USA)
and GraphPad Prism 6 software. Means and standard deviations are
shown in the ﬁgures. Pairwise signiﬁcances were calculated using
one-way ANOVA and two-tailed unpaired t-test. For Rms values, an
unpaired two-tailed nonparametric Mann–Whitney test was used. The
p-values lower than 0.05 were considered signiﬁcant.3. Results and discussion
Prostate carcinoma is the third leading cause of oncologic deaths
following lung and colorectal cancers and has the highest incidence
rate among all cancers in men [49]. For prostate cancer treatment,
options are currently hormone therapy, surgery, or irradiation [50,51].
Despite the available therapeutic arsenal, prostate cancer cells do not re-
spond well to single or multiple drug regimens [52,53] and side effects
are very signiﬁcant. New peptide-based drugs might be an alternative
[8,9,54]. For hematological malignancies, similar obstacles in treatment
have been described due to the existence ofmultiple cell typeswith var-
iable genotype/karyotype [55],which limits the beneﬁts of conventional
therapies for leukemia eradication.Fig. 2.Morphological examination of tumor cells using atomic force microscopy (AFM). Differ
projections of human prostate adenocarcinoma (PC-3) cells in the absence and presence of
morphology that is compromised after incubation with HNP-1.3.1. HNP-1 cytotoxic activity and correlation with cell membrane surface
charge
The HNP-1 cytotoxic activity against tumor cells was tested using a
live/dead viability/cytotoxicity assay kit. Fig. 1 shows the progression
of cell death and cell damage in response to HNP-1 concentration in
PC-3 and MOLT-4 cells. The concentrations of HNP-1 that are detected
in multiple clinical situations in moderate clinical states, severe infec-
tions, or tumor patients are variable [29,32,33,56]. Table S1 on Supple-
mentary Data gathers information from studies performed with HNPs
in normal and tumor cells, including the analysis of their heterogeneous
impact on cell viability and proliferation. In the viability experimentswe
performed, the concentration range tested was below the values ob-
served in severe infections [56] and within the range of the mitogenic
values of HNP-1 for cancers such as renal cell carcinoma [33]. Our results
show that HNP-1 is highly cytotoxic to PC-3 cells, in contrast with the
MOLT-4 cell line (Fig. 1). For PC-3 cells, an IC50 of 2.2 ± 0.3 μM was
obtained within the range of HNP-1 concentrations tested. At 10 μM,
more than 90% of PC-3 cells were dead, while for MOLT-4 cells the
same peptide concentration affected less than 30% of the cell popula-
tion. Side scatter ﬂow cytometry analysis showed an increase in granu-
larity concomitant with membrane permeabilization and cell death,
which raises the hypothesis that the peptide has a powerful effect on
PC-3 cellmorphology. Amuch lower degree of granularitywas observed
on MOLT-4 cells in parallel to the lower toxicity values. It is reasonable
to speculate that HNP-1 anticancer action comprises an initial step of
cell membrane permeabilization followed by increased granularity
due to apoptosis initiation. Mitochondria and nuclei perturbation to-
gether with the formation of apoptotic vesicles and chromatin conden-
sation are responsible for the increase in the granularity in this phase.
Cancer cell membranes are more anionic at their surface than nor-
mal cells [7,20] because of the presence of the phosphatidylserine (PS)
phospholipid and negatively charged macromolecules such as glycos-
aminoglycans (GAGs) on the outer leaﬂet of the membrane [20,57].
The zeta potential reﬂects the electrostatic potential at the shear plane
of a scattering particle or cell, which in turn depends on charge densityential interference contrast (DIC) images, AFM error images, and three-dimensional (3D)
human neutrophil peptide-1 (HNP-1) are shown. Control cells show a typical epithelial
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surface electrostatics of cells in different environmental states [59]
but also for assessing cellular phenomena such as adhesion and interac-
tion with peptides [10,60–63]. Therefore, we next evaluated the zetaFig. 3.Tumor cell topography revealed by atomic forcemicroscopy (AFM). Representative AFMh
absence and presence of humanneutrophil peptide-1 (HNP-1) are represented inA.Height proﬁ
Cell height normalized to control from 12 control cells and 10HNP-1-treated cells are shown in
unpaired t-test was employed. **0.001 b p-value b 0.01.potential of live PC-3 and MOLT-4 cells in the presence of increasing
concentrations of HNP-1. Adding HNP-1 to PC-3 and MOLT-4 cells in-
creased the zeta potential from−19.6±1.9mV to−17.8±1.5mV, re-
spectively, toward neutralization (Fig. 1), which shows that the peptideeight images and cell height proﬁles of humanprostate adenocarcinoma (PC-3) cells in the
les reveal that in thepresence of HNP-1, cells appearﬂattenedwith nuclear fragmentation.
panel B. There is a statistically signiﬁcant difference between both cell groups. A two-tailed
Fig. 4. Cell membrane roughness and elasticity evaluation of human prostate cancer cells. (A) Human prostate adenocarcinoma (PC-3) cell roughness, Rms, was evaluated on the nuclear
and cytoplasm areas as well as over the entire cell from AFM height images. The cell was divided into a 2.5 × 2.5 μm grid and each one assigned as nuclear (yellow), cytoplasmic (red), or
cell (green). The Rms median of each group of squares corresponds to the ﬁnal Rms value of the cellular component (nuclei and cytoplasm). Rms of the whole cell was calculated as the
median of all squares analyzed (nuclei, cytoplasm, and cell boundaries). The absolute Rms values decrease after peptide treatment revealing perturbations of the cell membrane. Eleven
control cells (black) were compared to 16 HNP-1-treated cells (grey). (B) Cells' elasticity was determined by the normalized Young's modulus (E) calculation after indenting live cells.
HNP-1 caused a decrease in E, thus an increase in cell elasticity which reﬂects changes associated to cytoskeleton organization and nuclear integrity. A total of 59 control cells and 30
HNP-1-treated cells over at least three independent days were measured and analyzed. A two-tailed unpaired t-test was employed. *0.01 b p-value b 0.05; **0.001 b p-value b 0.01;
***0.0001 b p-value b 0.001; ****p-value b 0.0001.
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cell types may reﬂect different membrane compositions, which ulti-
mately can account for differences in cell behavior in the presence of
the peptide [64,65]. Indeed, the differential distribution of membrane
components contributing to the net anionic character of the cellular sur-
face, such as PS and charged gangliosides, has been identiﬁed as key-factors for the efﬁcacy and selectivity of biologically active peptides
[64,66]. It should be also stressed that similarly towhatwe have reported
before for a customizedACP [16] and contrary towhat has been described
for AMPs [10], killing preceded full neutralization of the cell's surface
potential for both malignant cells (Fig. 1). Thus, cell death is not directly
related to complete membrane charge neutralization.
314 D. Gaspar et al. / Biochimica et Biophysica Acta 1853 (2015) 308–3163.2. AFM imaging of human prostate cancer cells
Using AFM, we observed the direct membrane damage of HNP-1
on human prostate cancer (Fig. 2) and MOLT-4 cells (Supplementary
Data). Fig. 2 shows representative height AFM images at 5 μMHNP-1,
above the IC50. Under normal culture conditions, the PC-3 cells pres-
ent an epithelial morphology with variable dimensions, with a rela-
tively smooth and intact surface and with pseudopodia. The cell
nucleus is distinctively visible and appears as a raised area in white
in each image. After HNP-1 addition, cells suffered a variety of mor-
phological modiﬁcations. The cell shape became irregular and the
fragmentation of the nucleus was visible (Fig. 2). Cells also appeared
collapsed. Height proﬁles of the cells were drawn using JPK software
(Fig. 3). The observed cells' height decrease caused by HNP-1 treat-
ment (Fig. 3B) reﬂects important changes on the cells' cytoskeleton
structure after the peptide interaction with the cell membrane and
its entrance into the cell. Previous studies using K562 and Raji cells
have shown that even though defensins permeabilize plasma mem-
branes, this perturbationmight not be sufﬁcient to induce signiﬁcant
cytolysis [67]. Induction of DNA strand breaks occurs and is likely to
participate in the cell death caused by HNPs [67]. It was thus pro-
posed that at least two mechanisms of cell injury occur, ﬁrst, a mem-
brane attack and, second, a major DNA injury (after 4–6 h of peptide
incubation). A different study also showed that HNP-1-induced
Trypanosoma cruzi cell destruction after early internalization through
pores on the cellular and ﬂagellar membranes [68]. There was minimal
cellular damage followed by cytoplasm and organelle damage and DNA
fragmentation. Our results extend these observations and indicate that
DNA injury occurs by chromatin condensation also in solid tumor cells.
Interestingly, at the same tested concentration HNP-1 did not induce
the collapse of MOLT-4 cells (please refer to online Supplementary
Data, Figs. S1 and S2 of this article), which contrasts with previous
studies on K562 (chronic myeloid leukemia) and Raji (Burkitt's
lymphoma) cells and suggests heterogeneity in the sensitivity to
HNP-1, and possibly other ACPs, within hematological cancers.
The cell membrane composition might have an important role in
this heterogeneity [64,66].
The roughness of the cell membrane is an indicator of the homeosta-
sis of cells because it can be related to different cellularmechanisms such
as motility and adhesion [69,70]. Further studies show that roughness
helps elucidating the mechanism of cellular death caused by external
molecules. For instance, surface roughness has been used to characterize
themetal-induced cytotoxic effects on pancreatic cells [71]. We have de-
termined the root-mean-square roughness, Rms, on AFM height images
on 4–5 different selected areas (2.5 × 2.5 μm) using Gwyddion 2.33 ver-
sion software [47]. The results are shown in Fig. 4A and reveal a general-
ized decrease in the membrane roughness after HNP-1 treatment.
Membrane roughness is sensitive to the membrane-skeleton interface
structure and integrity [72–74]. Membrane roughness decreases when
there is a weaker mechanical support provided by the cell cytoskeleton
to the lipid bilayer. This has been observed, for example, in red blood
cells in some blood pathologies and after treatment with cytoskeleton-
depolymerizing agents [73]. The detachment of the cytoskeleton net-
work from the lipid bilayer results in this decreased support and in a sub-
sequent folding and rearrangement of the lipid bilayer [73].
3.3. Nanoindentation of prostate tumor cells after HNP-1 treatment and
Young's modulus (E) determination
Cancer cells provide their own growth signalswhile ignoring growth
inhibitory signals, avoid cell death, replicate without limit, sustain an-
giogenesis, and invade tissues through basementmembranes and capil-
lary walls. As a dynamic system, cancer cells continuously adapt their
physical and chemical properties and their deformability. This has im-
plications in many cellular processes such as signaling, cytoadherence,
migration, invasion, and metastatic ability [75]. Indeed, for tumor cellsto metastasize, it is necessary that epithelial cancer cells penetrate the
endothelial layer and this step depends on both cell elasticity and
deformability [75]. It has been reported that tumor cells have a low elas-
ticity module and thus are softer than normal cells [39,75–78], and
others have proposed that this is related to metastatic potential [79].
There are several techniques available for measuring and assessing
mechanical properties of human cells [80–82] having AFM assumed
an important position [43,79,83,84]. In these experiments, a local defor-
mation is induced on the cell surface by using a blunt tip on the free end
of a cantilever. Force curves are obtained and the deformability or compli-
ance of normal andmalignant cells is retrieved from the elastic modulus.
This approach has been used before with particular relevance on the
work of Plodinec and coworkers. In this particular case, an indentation-
type AFM (IT-AFM) was used to reveal the stiffness proﬁle of normal/
benign and malignant tissues obtained from breast biopsies [85].
The importance of indentation studies is highlighted in this work, in
which mechanobiological markers for tumor development and clinical
prognostics were identiﬁed [85]. Other applications of force curve analy-
sis include the monitoring of the nanomechanical properties of different
biological samples while changing environmental conditions [86–88].
Elasticity values of PC-3 cells were obtained in live cells using a
pyramidal-shaped tip and by indenting the cell body. The obtained indi-
vidual force-displacement curves were converted into force–distance
curves (F–d), and ﬁnally these curves were shifted to remove the offset.
Fig. 4B shows the normalized values of E obtained for control and
HNP-1-treated cells at 5 μM after analyzing the indentation portion of
the F–d curves and application of the Hertz model with JPK software.
The relative change of the elastic modulus is used to monitor the effect
of externalmolecules on the deformability of cells [89]. However, values
of E for mammalian cells have a great variability [90]. The mechanical
behavior of the cell surface includes typically elastic and viscous compo-
nents [91]. As cytoskeleton components are known to be heterogeneous
in their elastic moduli, dimensions, and also distribution [92], variable
cell stiffness and consequently variable E values are to be expected. In
this study, E values reﬂect mainly local mechanical information. Several
parameters were controlled to reduce data variability. Local elasticity
information was collected with controlled force, velocity, and indenta-
tion depth so the contribution of viscous component as well as the
contribution of cell structures underneath the membrane could be
minimized. Three curves were collected from each analyzed cell and no
signiﬁcant changes were observed between them. Fig. S3 on the online
Supplementary data represents typical force curves. Our results show
that HNP-1-treated cells have a lower E, revealing a change in their
mechanical properties. This effect is related to internal damage in the
cytoskeleton and/or nuclear region and reﬂects the apoptotic effect of
the peptide [70] in agreement with AFM images and zeta potential
measurements. These changes in cell's elasticity are expected to hamper
both cell motility and ability to deform/spread, therefore inﬂuencing
subsequent invasion and metastasis to other organs such as bones.
4. Conclusions
In this study, we apply an innovative combination of techniques to
study the effects of HNP-1 on cells of solid and hematological tumors.
Cytotoxicity experiments and measurements of membrane surface
charge of solid and hematological tumor cell lines revealed a preferential
activity of HNP-1 toward solid tumors. Differences in the membrane
composition of both types of tumors are expected to be behind the
peptide's selectivity. In this regard, it is tempting to speculate that the
substantial membrane alterations that solid tumor cells must undergo
to overcome the physical barriers imposed on epithelial cells, as opposed
to the minimal constrains imposed on hematopoietic cells, may render
the former more sensitive to the cytotoxic effect of ACPs. Recent studies
pinpoint the importance of sialic acid moieties of glycoproteins or gan-
gliosides on the surface of breast cancer cells which represent binding
sites for AMPs [93]. The expression of both these molecules and also of
315D. Gaspar et al. / Biochimica et Biophysica Acta 1853 (2015) 308–316the lipids of the membrane bilayer can be expected to vary between
different cancers and between solid and non-solid tumors [94], thus
functioning as a trigger for ACPs selectivity and accounting for a strong
binding ability for somepeptides. Our results are consistentwithHNP-1
translocation to the interior of the cell and subsequent nuclear DNA and
cytoskeleton damage. The end result is cell collapse due to apoptosis.
Overall, we show that cell death occurs without full neutralization of
the cancer cell membrane, which distinguishes ACPs' from AMPs'
mode of action. Although the identiﬁcation of the exact cancers where
its use may be most effective warrants further investigation, HNP-1
shows great potential as a powerful ACP drug lead.
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